<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01233284</url>
  </required_header>
  <id_info>
    <org_study_id>205.380</org_study_id>
    <secondary_id>2010-018471-26</secondary_id>
    <nct_id>NCT01233284</nct_id>
  </id_info>
  <brief_title>Randomised, Double- Blind, Cross-over Efficacy and Safety Comparison of Three Different Doses of Tiotropium Administered Once Daily Versus Placebo in Patients With Moderate Persistent Asthma.</brief_title>
  <official_title>A Phase II Randomised, Double-blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Three Doses of Tiotropium Inhalation Solution Delivered Via Respimat Inhaler (1.25, 2.5 and 5.0 Mcg Once Daily) Versus Placebo in Patients With Moderate Persistent Asthma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Rationale for the current trial is to evaluate the efficacy and safety of three doses (1.25
      µg, 2.5 µg and 5.0 µg ex mouthpiece) of tiotropium inhalation solution in patients with
      moderate persistent asthma who are still symptomatic despite regular maintenance therapy with
      inhaled corticosteroids (ICS).

      The data collected in the present trial will provide useful information to health care
      providers and patients regarding the efficacy and safety of a once daily inhalation of three
      different doses of tiotropium solution delivered by the Respimat® inhaler in addition to
      inhaled corticosteroids in the treatment of not fully controlled moderate asthma in
      comparison to placebo. The Pharmacokinetics (PK) of tiotropium is well established in COPD
      patients. However, there is currently no PK data available for the 3 doses of tiotropium
      being tested in this trial in patients with moderate persistent asthma. Tiotropium is a once
      daily drug. Hence, the rationale for blood and urine sampling for PK analysis over 24 hours
      in a subset of patients is to confirm the PK of the 3 doses in moderate asthma patients.
      Rationale for the 24-hour pulmonary function test sub-investigation is to demonstrate that a
      once daily dosing of tiotropium inhalation solution is effective and safe in the treatment of
      moderate persistent asthma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1) Peak Within 0-3 Hours Post-dose Response</measure>
    <time_frame>10 minutes (min) before drug administration and 30 min, 1h, 2h, 3h after drug administration</time_frame>
    <description>Mixed model repeated measurement (MMRM) results. Response was defined as change from baseline at the end of of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Response</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>MMRM results. Response was defined as change from baseline at the end of of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. Trough FEV1 was measured just prior to the last administration of randomised treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 Area Under the Curve 0-3 Hours (AUC0-3h) Response</measure>
    <time_frame>10 minutes (min) before drug administration and 30 min, 1h, 2h, 3h after drug administration</time_frame>
    <description>MMRM results. Response was defined as change from baseline at the end of of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. FEV1 AUC0-3h was calculated using the trapezoidal rule divided by the observation time (3 hours) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC) Peak Within 0-3 Hours Post-dose Response</measure>
    <time_frame>10 minutes (min) before drug administration and 30 min, 1h, 2h, 3h after drug administration</time_frame>
    <description>MMRM results. Response was defined as change from baseline at the end of of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Response</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>MMRM results. Response was defined as change from baseline at the end of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. Trough FVC was measured just prior to the last administration of randomised treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC AUC0-3h Response</measure>
    <time_frame>10 minutes (min) before drug administration and 30 min, 1h, 2h, 3h after drug administration</time_frame>
    <description>MMRM results. Response was defined as change from baseline at the end of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. FVC AUC0-3h was calculated using the trapezoidal rule divided by the observation time (3 hours) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual FEV1 Over Time (at Each Timepoint at Visits) Response</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>MMRM results. Response was defined as change from baseline at the end of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual FVC Over Time (at Each Timepoint at Visits) Response</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>MMRM results. Response was defined as change from baseline at the end of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual Peak Expiratory Flow (PEF) Over Time (at Each Timepoint at Visits) Response</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>MMRM results. Response was defined as change from baseline at the end of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Pre-dose Morning PEF (PEF a.m.) Response During the Last Week on Treatment</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>MMRM results. Response was defined as change from baseline at the end of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. Weekly means obtained during the last week of each period of randomised treatment will be compared (measured by patients at home using the AM2+ device).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Pre-dose Evening PEF (PEF p.m.) Response During the Last Week on Treatment</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>MMRM results. Response was defined as change from baseline at the end of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. Weekly means obtained during the last week of each period of randomised treatment will be compared (measured by patients at home using the AM2+ device).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEF Variability Response (Last Week on Treatment)</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>MMRM results. Response was defined as change from baseline at the end of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. PEF variability is the absolute difference between morning and evening PEF value divided by the mean of these two values, expressed as a percent . Weekly means obtained during the last week of each period of randomised treatment will be compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Puffs of Rescue Medication During the Whole Day (Last Week on Treatment, Response Values)</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>MMRM results. Response was defined as change from baseline at the end of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. Weekly means obtained during the last week of each period of randomised treatment will be compared (measured by patients at home using the AM2+ device).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Puffs of Rescue Medication During Daytime (Last Week on Treatment, Response Values)</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>MMRM results. Response was defined as change from baseline at the end of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. Weekly means obtained during the last week of each period of randomised treatment will be compared (measured by patients at home using the AM2+ device).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Puffs of Rescue Medication During Nighttime (Last Week on Treatment, Response Values)</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>MMRM results. Response was defined as change from baseline at the end of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. Weekly means obtained during the last week of each period of randomised treatment will be compared (measured by patients at home using the AM2+ device).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Night Awakenings During the Last Week on Treatment (Score, Response Values)</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>MMRM results. Response was defined as change from baseline at the end of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. Weekly means obtained during the last week of each period of randomised treatment will be compared (measured by patients at home using the AM2+ device).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 Area Under the Curve Within 24 Hours (h) Response (FEV1 AUC0-12h, FEV1 AUC12-24h, FEV1 AUC0-24h)</measure>
    <time_frame>10 minutes (min) before drug administration and 30 min, 1h, 2h, 3h, 4h, 11h 50min, 12h 30min, 13h, 14h, 15h, 16h, 18h, 20h, 22h, 23h, 23h 50min after drug administration</time_frame>
    <description>MMRM results. Response was defined as change from baseline at the end of of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. FEV1 AUC0-12, FEV1 AUC12-24 and FEV1 AUC0-24 were calculated using the trapezoidal rule divided by the observation time (12h resp. 24h) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC Area Under the Curve Within 24 Hours (h) Response (FVC AUC0-12h, FVC AUC12-24h, FVC AUC0-24h)</measure>
    <time_frame>10 minutes (min) before drug administration and 30 min, 1h, 2h, 3h, 4h, 11h 50min, 12h 30min, 13h, 14h, 15h, 16h, 18h, 20h, 22h, 23h, 23h 50min after drug administration</time_frame>
    <description>MMRM results. Response was defined as change from baseline at the end of of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. FVC AUC0-12, FVC AUC12-24 and FVC AUC0-24 were calculated using the trapezoidal rule divided by the observation time (12h resp. 24h) to report in litres.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">149</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>tiotropium low dose once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily, delivered by the Respimat® inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tiotropium medium dose once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily, delivered by the Respimat® inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tiotropium high dose once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily, delivered by the Respimat® inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo once daily</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>once daily, delivered by the Respimat® inhaler</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium bromide 2.5µg once daily</intervention_name>
    <description>Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo</description>
    <arm_group_label>tiotropium medium dose once daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium matching Placebo once daily</intervention_name>
    <description>Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo</description>
    <arm_group_label>Placebo once daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium bromide high dose once daily</intervention_name>
    <description>Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo</description>
    <arm_group_label>tiotropium high dose once daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium bromide 1.25µg once daily</intervention_name>
    <description>IMP</description>
    <arm_group_label>tiotropium low dose once daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. All patients must sign and date an Informed Consent Form consistent with the
             Harmonised Tripartite Guideline for Good Clinical Practice (ICH-GCP) and local
             legislation prior to participation in the trial (i.e. prior to any trial procedures,
             including any pre-trial washout of medications and medication restrictions for
             pulmonary function test at Visit 1).

          2. Male or female patients aged between 18 and 75 years (at date of informed consent).

          3. All patients must have at least a 3 month history of asthma at the time of enrolment
             into the trial. The diagnosis should be confirmed at Visit 1 by fulfilling inclusion
             criterion no. 5.

          4. The initial diagnosis of asthma must have been made before the patient's age of 40.

          5. The diagnosis of asthma has to be confirmed at Visit 1 with a bronchodilator
             reversibility (15 to 30 minutes after 4 puffs of 100 µg salbutamol) resulting in a
             Forced Expiratory Volume in one second (FEV1) increase of = 12% and = 200mL.

          6. All patients must have been on maintenance treatment with a medium, stable dose of
             inhaled corticosteroids (alone or in a fixed combination with a long acting or short
             acting beta agonist [LABA or SABA]) for at least 4 weeks prior to Visit 1.

          7. All patients must be symptomatic at Visit 1 (screening) and prior to randomisation at
             Visit 2 as defined by an Asthma Control Questionnaire (ACQ) mean score of = 1.5.

          8. All patients must have a pre-bronchodilator FEV1 = 60% and = 90% of predicted normal
             at Visit 1. Predicted normal values will be calculated according to the European
             Community for Steel and Coal (ECSC).

          9. Variation of absolute FEV1 values of Visit 1 (pre-bronchodilator) as compared to Visit
             2 (pre-dose) must be within ± 30%.

         10. Patients must be never-smokers or ex-smokers who stopped smoking at least one year
             prior to enrolment (Visit 0) and who have a smoking history of less than 10 pack
             years.

         11. Patients must be able to use the Respimat® inhaler correctly.

         12. Patients must be able to perform all trial related procedures including technically
             acceptable pulmonary function tests and use of electronic diary/peak flow meter (diary
             compliance of at least 80% is required).

        Exclusion criteria:

          1. Patients with a significant disease other than asthma.

          2. Patients with a clinically relevant abnormal screening (Visit 1) haematology or blood
             chemistry if the abnormality defines a significant disease as defined in exclusion
             criterion 1.

          3. Patients with a recent history (i.e. six months or less) of myocardial infarction.

          4. Patients who have been hospitalised for cardiac failure during the past year.

          5. Patients with any unstable or life-threatening cardiac arrhythmia or cardiac
             arrhythmia requiring intervention or a change in drug therapy within the past year.

          6. Patients with lung diseases other than asthma.

          7. Patients with known active tuberculosis.

          8. Patients with malignancy for which the patient has undergone resection, radiation
             therapy or chemotherapy within the last five years.

          9. Patients who have undergone thoracotomy with pulmonary resection. Patients with a
             history of thoracotomy for other reasons should be evaluated as per exclusion
             criterion no. 1.

         10. Patients with known moderate to severe renal impairment.

         11. Patients with known narrow angle glaucoma or any other disease where anticholinergic
             treatment is contraindicated.

         12. Patients with significant symptomatic prostatic hyperplasia or bladder-neck
             obstruction. Patients whose symptoms are controlled on treatment may be included.

         13. Patients with significant alcohol or drug abuse within the past two years (to the
             discretion of the investigator).

         14. Patients who are currently in a pulmonary rehabilitation program or have completed
             pulmonary rehabilitation program in the 6 weeks prior to Visit 1 (screening) or who
             will start a rehabilitation program during the study.

         15. Patients with known hypersensitivity to anticholinergic drugs, Benzalkonium chloride
             (BAC), Ethylenediaminetetraacetate (EDTA) or any other components of the study
             medication delivery system (Respimat®/ tiotropium inhalation solution).

         16. Pregnant or nursing woman.

         17. Women of childbearing potential not using a highly effective method of birth control.

         18. Patients who have taken an investigational drug within four weeks prior to Visit 1.

         19. Patients who have been treated with beta-blocker medication within four weeks prior to
             Visit 1 and/or during the screening period (period between Visit 1 and Visit 2).
             Topical cardio-selective beta-blocker eye medications for non-arrow angle glaucoma are
             allowed.

         20. Patients who have been treated with the long-acting anticholinergic tiotropium
             (Spiriva®) within four weeks prior to Visit 1 and/or during the screening period
             (period between Visit 1 and Visit 2).

         21. Patients who have been treated with oral or patch beta-adrenergics within four weeks
             prior to Visit 1 and/or during the Screening period (period between Visit 1 and Visit
             2)

         22. Patients who have been treated with oral corticosteroids within four weeks prior to
             Visit 1 and/or during the screening period.

         23. Patients who have been treated with anti-Immunoglobuline E (anti-IgE) antibodies, e.g.
             omalizumab, within 6 months prior to Visit 1 and/or during the screening period
             (period between Visit 1 and Visit 2).

         24. Patients who have been treated with cromone within two weeks prior to Visit 1 and/or
             during the screening period (period between Visit 1 and Visit 2).

         25. Patients who have been treated with methylxanthines or phosphodiesterase 4 inhibitors
             within two weeks prior to Visit 1 and/or during the screening period (period between
             Visit 1 and Visit 2).

         26. Patients who have been treated with other non-approved and according to international
             guidelines not recommended experimental drugs for routine asthma therapy (e.g. Tumor
             Necrosis Factor (TNF)-alpha blockers, methotrexate, cyclosporin) within four weeks
             prior to Visit 1 and/or during the screening period (period between Visit 1 and Visit
             2).

         27. Patient with any asthma exacerbation or respiratory tract infection in the 4 weeks
             prior to visit 1 and/or during the screening period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>205.380.43002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hallein</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.380.43004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.380.43005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Neumarkt am Wallersee</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.380.43001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Schlüsslberg</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.380.43003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Thalheim bei Wels</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.380.49006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.380.49010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.380.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.380.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.380.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.380.49009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.380.49008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Schwerin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.380.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.380.49005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wiesloch</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.380.38005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.380.38003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.380.38004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.380.38001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.380.38002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2010</study_first_submitted>
  <study_first_submitted_qc>November 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2010</study_first_posted>
  <results_first_submitted>December 14, 2012</results_first_submitted>
  <results_first_submitted_qc>December 14, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 21, 2013</results_first_posted>
  <last_update_submitted>November 27, 2013</last_update_submitted>
  <last_update_submitted_qc>November 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 149 patients were randomised and treated, 141 patients completed the trial.</recruitment_details>
      <pre_assignment_details>Randomised, double-blind, placebo controlled, cross-over design without washout phase between the four periods. Patients were randomized to one of the 4 sequences (ABCD, DCBA, BDAC, CADB). For one patient treatment 2 and treatment 3 were interchanged (resulting sequence DBCA).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tio R5 Once Daily(qd)/Tio R1.25 qd/Placebo/Tio R2.5 qd</title>
          <description>Patients treated with Tiotropium 5 mcg in period 1 (evening), with Tiotropium 1.25 mcg in period 2 (evening), with a matching Placebo in period 3 (evening) and with Tiotropium 2.5 mcg in period 4 (evening). All products were delivered by the Respimat inhaler as add-on therapy to inhaled corticosteroids (ICS). No washouts (off-treatment periods) between treatments. Duration of each treatment period was 4 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Tio R2.5 qd/Placebo/Tio R1.25 qd/Tio R5 qd</title>
          <description>Patients treated with Tiotropium 2.5 mcg in period 1 (evening), with a matching Placebo in period 2 (evening), with Tiotropium 1.25 mcg in period 3 (evening) and with Tiotropium 5 mcg in period 4 (evening). All products were delivered by the Respimat inhaler as add-on therapy to ICS. No washouts (off-treatment periods) between treatments. Duration of each treatment period was 4 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Tio R1.25 qd/Tio R2.5 qd/Tio R5 qd/Placebo</title>
          <description>Patients treated with Tiotropium 1.25 mcg in period 1 (evening), with Tiotropium 2.5 mcg in period 2 (evening), with Tiotropium 5 mcg in period 3 (evening) and with a matching placebo in period 4 (evening). All products were delivered by the Respimat inhaler as add-on therapy to inhaled corticosteroid ICS. No washouts (off-treatment periods) between treatments. Duration of each treatment period was 4 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Placebo/Tio R5 qd/Tio R2.5 qd/Tio R1.25 qd</title>
          <description>Patients treated with a matching Placebo in period 1 (evening), with Tiotropium 5 mcg in period 2 (evening), with Tiotropium 2.5 mcg in period 3 (evening) and with Tiotropium 1.25 mcg in period 4 (evening). All products were delivered by the Respimat inhaler as add-on therapy to ICS. No washouts (off-treatment periods) between treatments. Duration of each treatment period was 4 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Placebo/Tio R2.5 qd/Tio R5 qd/Tio R1.25 qd</title>
          <description>Patient treated with a matching Placebo in period 1 (evening), with Tiotropium 2.5 mcg in period 2 (evening), with Tiotropium 5 mcg in period 3 (evening) and with Tiotropium 1.25 mcg in period 4 (evening). All products were delivered by the Respimat inhaler as add-on therapy to ICS. No washouts (off-treatment periods) between treatments. Duration of each treatment period was 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1 (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="38"/>
                <participants group_id="P4" count="35"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="35"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2 (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="35"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="35"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 3 (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="35"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="35"/>
                <participants group_id="P4" count="34"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 4 (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="35"/>
                <participants group_id="P4" count="34"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="35"/>
                <participants group_id="P4" count="33"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Baseline Total</title>
          <description>Total number of patients randomised and treated in the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="149"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.3" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Forced Expiratory Volume in One Second (FEV1) Peak Within 0-3 Hours Post-dose Response</title>
        <description>Mixed model repeated measurement (MMRM) results. Response was defined as change from baseline at the end of of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline.</description>
        <time_frame>10 minutes (min) before drug administration and 30 min, 1h, 2h, 3h after drug administration</time_frame>
        <population>Full analysis set (FAS) reduced to patients with non-missing FEV1 data. The FAS is defined as patients randomised, treated, with baseline data and at least one on-treatment efficacy measurement after 4 weeks on treatment within a period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo qd in the evening delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25 qd</title>
            <description>Tiotropium 1.25 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5 qd</title>
            <description>Tiotropium 2.5 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second (FEV1) Peak Within 0-3 Hours Post-dose Response</title>
          <description>Mixed model repeated measurement (MMRM) results. Response was defined as change from baseline at the end of of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline.</description>
          <population>Full analysis set (FAS) reduced to patients with non-missing FEV1 data. The FAS is defined as patients randomised, treated, with baseline data and at least one on-treatment efficacy measurement after 4 weeks on treatment within a period.</population>
          <units>Litre</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="144"/>
                <count group_id="O4" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.116" spread="0.027"/>
                    <measurement group_id="O2" value="0.255" spread="0.027"/>
                    <measurement group_id="O3" value="0.244" spread="0.027"/>
                    <measurement group_id="O4" value="0.304" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.138</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.090</ci_lower_limit>
            <ci_upper_limit>0.186</ci_upper_limit>
            <estimate_desc>Tio R1.25 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.128</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.080</ci_lower_limit>
            <ci_upper_limit>0.176</ci_upper_limit>
            <estimate_desc>Tio R2.5 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.188</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.140</ci_lower_limit>
            <ci_upper_limit>0.236</ci_upper_limit>
            <estimate_desc>Tio R5 qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Response</title>
        <description>MMRM results. Response was defined as change from baseline at the end of of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. Trough FEV1 was measured just prior to the last administration of randomised treatment.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>FAS reduced to patients with non-missing FEV1 data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo qd in the evening delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25 qd</title>
            <description>Tiotropium 1.25 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5 qd</title>
            <description>Tiotropium 2.5 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response</title>
          <description>MMRM results. Response was defined as change from baseline at the end of of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. Trough FEV1 was measured just prior to the last administration of randomised treatment.</description>
          <population>FAS reduced to patients with non-missing FEV1 data.</population>
          <units>Litre</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="144"/>
                <count group_id="O4" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.006" spread="0.027"/>
                    <measurement group_id="O2" value="0.131" spread="0.027"/>
                    <measurement group_id="O3" value="0.138" spread="0.027"/>
                    <measurement group_id="O4" value="0.149" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.125</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.078</ci_lower_limit>
            <ci_upper_limit>0.173</ci_upper_limit>
            <estimate_desc>Tio R1.25 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.132</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.084</ci_lower_limit>
            <ci_upper_limit>0.179</ci_upper_limit>
            <estimate_desc>Tio R2.5 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.143</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.096</ci_lower_limit>
            <ci_upper_limit>0.191</ci_upper_limit>
            <estimate_desc>Tio R5 qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 Area Under the Curve 0-3 Hours (AUC0-3h) Response</title>
        <description>MMRM results. Response was defined as change from baseline at the end of of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. FEV1 AUC0-3h was calculated using the trapezoidal rule divided by the observation time (3 hours) to report in litres.</description>
        <time_frame>10 minutes (min) before drug administration and 30 min, 1h, 2h, 3h after drug administration</time_frame>
        <population>FAS reduced to patients with non-missing FEV1 data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo qd in the evening delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25 qd</title>
            <description>Tiotropium 1.25 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5 qd</title>
            <description>Tiotropium 2.5 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Area Under the Curve 0-3 Hours (AUC0-3h) Response</title>
          <description>MMRM results. Response was defined as change from baseline at the end of of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. FEV1 AUC0-3h was calculated using the trapezoidal rule divided by the observation time (3 hours) to report in litres.</description>
          <population>FAS reduced to patients with non-missing FEV1 data.</population>
          <units>Litre</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="144"/>
                <count group_id="O4" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" spread="0.027"/>
                    <measurement group_id="O2" value="0.154" spread="0.027"/>
                    <measurement group_id="O3" value="0.152" spread="0.027"/>
                    <measurement group_id="O4" value="0.203" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.129</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.083</ci_lower_limit>
            <ci_upper_limit>0.175</ci_upper_limit>
            <estimate_desc>Tio R1.25 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.127</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.081</ci_lower_limit>
            <ci_upper_limit>0.172</ci_upper_limit>
            <estimate_desc>Tio R2.5 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.178</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.132</ci_lower_limit>
            <ci_upper_limit>0.224</ci_upper_limit>
            <estimate_desc>Tio R5 qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC) Peak Within 0-3 Hours Post-dose Response</title>
        <description>MMRM results. Response was defined as change from baseline at the end of of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline.</description>
        <time_frame>10 minutes (min) before drug administration and 30 min, 1h, 2h, 3h after drug administration</time_frame>
        <population>FAS reduced to patients with non-missing FVC data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo qd in the evening delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25 qd</title>
            <description>Tiotropium 1.25 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5 qd</title>
            <description>Tiotropium 2.5 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC) Peak Within 0-3 Hours Post-dose Response</title>
          <description>MMRM results. Response was defined as change from baseline at the end of of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline.</description>
          <population>FAS reduced to patients with non-missing FVC data.</population>
          <units>Litre</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="144"/>
                <count group_id="O4" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.092" spread="0.034"/>
                    <measurement group_id="O2" value="0.171" spread="0.034"/>
                    <measurement group_id="O3" value="0.163" spread="0.034"/>
                    <measurement group_id="O4" value="0.229" spread="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0034</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.079</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.026</ci_lower_limit>
            <ci_upper_limit>0.132</ci_upper_limit>
            <estimate_desc>Tio R1.25 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0087</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.071</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.018</ci_lower_limit>
            <ci_upper_limit>0.124</ci_upper_limit>
            <estimate_desc>Tio R2.5 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.137</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.085</ci_lower_limit>
            <ci_upper_limit>0.190</ci_upper_limit>
            <estimate_desc>Tio R5 qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Response</title>
        <description>MMRM results. Response was defined as change from baseline at the end of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. Trough FVC was measured just prior to the last administration of randomised treatment.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>FAS reduced to patients with non-missing FVC data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo qd in the evening delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25 qd</title>
            <description>Tiotropium 1.25 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5 qd</title>
            <description>Tiotropium 2.5 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Response</title>
          <description>MMRM results. Response was defined as change from baseline at the end of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. Trough FVC was measured just prior to the last administration of randomised treatment.</description>
          <population>FAS reduced to patients with non-missing FVC data.</population>
          <units>Litre</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="144"/>
                <count group_id="O4" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004" spread="0.035"/>
                    <measurement group_id="O2" value="0.058" spread="0.035"/>
                    <measurement group_id="O3" value="0.076" spread="0.035"/>
                    <measurement group_id="O4" value="0.102" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0732</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.054</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.030</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.005</ci_lower_limit>
            <ci_upper_limit>0.113</ci_upper_limit>
            <estimate_desc>Tio R1.25 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0177</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.072</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.030</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.012</ci_lower_limit>
            <ci_upper_limit>0.131</ci_upper_limit>
            <estimate_desc>Tio R2.5 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0012</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.098</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.030</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.039</ci_lower_limit>
            <ci_upper_limit>0.157</ci_upper_limit>
            <estimate_desc>Tio R5 qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC AUC0-3h Response</title>
        <description>MMRM results. Response was defined as change from baseline at the end of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. FVC AUC0-3h was calculated using the trapezoidal rule divided by the observation time (3 hours) to report in litres.</description>
        <time_frame>10 minutes (min) before drug administration and 30 min, 1h, 2h, 3h after drug administration</time_frame>
        <population>FAS reduced to patients with non-missing FVC data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo qd in the evening delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25 qd</title>
            <description>Tiotropium 1.25 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5 qd</title>
            <description>Tiotropium 2.5 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC AUC0-3h Response</title>
          <description>MMRM results. Response was defined as change from baseline at the end of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. FVC AUC0-3h was calculated using the trapezoidal rule divided by the observation time (3 hours) to report in litres.</description>
          <population>FAS reduced to patients with non-missing FVC data.</population>
          <units>Litre</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="144"/>
                <count group_id="O4" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.028" spread="0.034"/>
                    <measurement group_id="O2" value="0.036" spread="0.034"/>
                    <measurement group_id="O3" value="0.047" spread="0.034"/>
                    <measurement group_id="O4" value="0.110" spread="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0149</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.064</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.013</ci_lower_limit>
            <ci_upper_limit>0.115</ci_upper_limit>
            <estimate_desc>Tio R1.25 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0043</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.075</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.024</ci_lower_limit>
            <ci_upper_limit>0.126</ci_upper_limit>
            <estimate_desc>Tio R2.5 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.138</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.086</ci_lower_limit>
            <ci_upper_limit>0.189</ci_upper_limit>
            <estimate_desc>Tio R5 qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual FEV1 Over Time (at Each Timepoint at Visits) Response</title>
        <description>MMRM results. Response was defined as change from baseline at the end of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>FAS reduced to patients with non-missing FEV1 data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo qd in the evening delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25 qd</title>
            <description>Tiotropium 1.25 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5 qd</title>
            <description>Tiotropium 2.5 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
        </group_list>
        <measure>
          <title>Individual FEV1 Over Time (at Each Timepoint at Visits) Response</title>
          <description>MMRM results. Response was defined as change from baseline at the end of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline.</description>
          <population>FAS reduced to patients with non-missing FEV1 data.</population>
          <units>Litre</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="144"/>
                <count group_id="O4" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Timepoint -0:10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.006" spread="0.027"/>
                    <measurement group_id="O2" value="0.131" spread="0.027"/>
                    <measurement group_id="O3" value="0.138" spread="0.027"/>
                    <measurement group_id="O4" value="0.149" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 0:30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.029" spread="0.028"/>
                    <measurement group_id="O2" value="0.160" spread="0.028"/>
                    <measurement group_id="O3" value="0.163" spread="0.028"/>
                    <measurement group_id="O4" value="0.209" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 1:00</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.026" spread="0.029"/>
                    <measurement group_id="O2" value="0.148" spread="0.029"/>
                    <measurement group_id="O3" value="0.156" spread="0.029"/>
                    <measurement group_id="O4" value="0.205" spread="0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 2:00</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.033" spread="0.029"/>
                    <measurement group_id="O2" value="0.158" spread="0.029"/>
                    <measurement group_id="O3" value="0.149" spread="0.029"/>
                    <measurement group_id="O4" value="0.218" spread="0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 3:00</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.013" spread="0.029"/>
                    <measurement group_id="O2" value="0.160" spread="0.029"/>
                    <measurement group_id="O3" value="0.148" spread="0.029"/>
                    <measurement group_id="O4" value="0.191" spread="0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual FVC Over Time (at Each Timepoint at Visits) Response</title>
        <description>MMRM results. Response was defined as change from baseline at the end of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>FAS reduced to patients with non-missing FVC data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo qd in the evening delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25 qd</title>
            <description>Tiotropium 1.25 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5 qd</title>
            <description>Tiotropium 2.5 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
        </group_list>
        <measure>
          <title>Individual FVC Over Time (at Each Timepoint at Visits) Response</title>
          <description>MMRM results. Response was defined as change from baseline at the end of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline.</description>
          <population>FAS reduced to patients with non-missing FVC data.</population>
          <units>Litre</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="144"/>
                <count group_id="O4" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Timepoint -0:10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004" spread="0.035"/>
                    <measurement group_id="O2" value="0.058" spread="0.035"/>
                    <measurement group_id="O3" value="0.076" spread="0.035"/>
                    <measurement group_id="O4" value="0.102" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 0:30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.028" spread="0.035"/>
                    <measurement group_id="O2" value="0.042" spread="0.035"/>
                    <measurement group_id="O3" value="0.060" spread="0.035"/>
                    <measurement group_id="O4" value="0.124" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 1:00</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.031" spread="0.036"/>
                    <measurement group_id="O2" value="0.024" spread="0.036"/>
                    <measurement group_id="O3" value="0.041" spread="0.036"/>
                    <measurement group_id="O4" value="0.112" spread="0.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 2:00</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.022" spread="0.036"/>
                    <measurement group_id="O2" value="0.037" spread="0.036"/>
                    <measurement group_id="O3" value="0.045" spread="0.036"/>
                    <measurement group_id="O4" value="0.119" spread="0.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 3:00</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.050" spread="0.036"/>
                    <measurement group_id="O2" value="0.036" spread="0.036"/>
                    <measurement group_id="O3" value="0.033" spread="0.036"/>
                    <measurement group_id="O4" value="0.078" spread="0.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual Peak Expiratory Flow (PEF) Over Time (at Each Timepoint at Visits) Response</title>
        <description>MMRM results. Response was defined as change from baseline at the end of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>FAS reduced to patients with non-missing PEF data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo qd in the evening delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25 qd</title>
            <description>Tiotropium 1.25 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5 qd</title>
            <description>Tiotropium 2.5 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
        </group_list>
        <measure>
          <title>Individual Peak Expiratory Flow (PEF) Over Time (at Each Timepoint at Visits) Response</title>
          <description>MMRM results. Response was defined as change from baseline at the end of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline.</description>
          <population>FAS reduced to patients with non-missing PEF data.</population>
          <units>Litre/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="144"/>
                <count group_id="O4" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Timepoint -0:10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.038" spread="4.804"/>
                    <measurement group_id="O2" value="30.567" spread="4.802"/>
                    <measurement group_id="O3" value="33.903" spread="4.804"/>
                    <measurement group_id="O4" value="34.787" spread="4.812"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 0:30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.235" spread="4.949"/>
                    <measurement group_id="O2" value="32.163" spread="4.947"/>
                    <measurement group_id="O3" value="37.149" spread="4.949"/>
                    <measurement group_id="O4" value="39.325" spread="4.957"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 1:00</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.095" spread="5.074"/>
                    <measurement group_id="O2" value="34.070" spread="5.072"/>
                    <measurement group_id="O3" value="36.851" spread="5.074"/>
                    <measurement group_id="O4" value="41.260" spread="5.082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 2:00</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.237" spread="5.039"/>
                    <measurement group_id="O2" value="34.544" spread="5.037"/>
                    <measurement group_id="O3" value="36.972" spread="5.039"/>
                    <measurement group_id="O4" value="42.694" spread="5.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 3:00</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.046" spread="5.024"/>
                    <measurement group_id="O2" value="34.620" spread="5.022"/>
                    <measurement group_id="O3" value="37.283" spread="5.024"/>
                    <measurement group_id="O4" value="40.624" spread="5.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Pre-dose Morning PEF (PEF a.m.) Response During the Last Week on Treatment</title>
        <description>MMRM results. Response was defined as change from baseline at the end of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. Weekly means obtained during the last week of each period of randomised treatment will be compared (measured by patients at home using the AM2+ device).</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>FAS reduced to patients with non-missing morning PEF data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo qd in the evening delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25 qd</title>
            <description>Tiotropium 1.25 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5 qd</title>
            <description>Tiotropium 2.5 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pre-dose Morning PEF (PEF a.m.) Response During the Last Week on Treatment</title>
          <description>MMRM results. Response was defined as change from baseline at the end of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. Weekly means obtained during the last week of each period of randomised treatment will be compared (measured by patients at home using the AM2+ device).</description>
          <population>FAS reduced to patients with non-missing morning PEF data.</population>
          <units>Litre/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="146"/>
                <count group_id="O4" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.395" spread="4.573"/>
                    <measurement group_id="O2" value="22.944" spread="4.543"/>
                    <measurement group_id="O3" value="22.290" spread="4.543"/>
                    <measurement group_id="O4" value="25.241" spread="4.559"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>18.550</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.737</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>11.204</ci_lower_limit>
            <ci_upper_limit>25.895</ci_upper_limit>
            <estimate_desc>Tio R1.25 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>17.895</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.737</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>10.550</ci_lower_limit>
            <ci_upper_limit>25.240</ci_upper_limit>
            <estimate_desc>Tio R2.5 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>20.846</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.739</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>13.497</ci_lower_limit>
            <ci_upper_limit>28.195</ci_upper_limit>
            <estimate_desc>Tio R5 qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Pre-dose Evening PEF (PEF p.m.) Response During the Last Week on Treatment</title>
        <description>MMRM results. Response was defined as change from baseline at the end of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. Weekly means obtained during the last week of each period of randomised treatment will be compared (measured by patients at home using the AM2+ device).</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>FAS reduced to patients with non-missing evening PEF data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo qd in the evening delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25 qd</title>
            <description>Tiotropium 1.25 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5 qd</title>
            <description>Tiotropium 2.5 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pre-dose Evening PEF (PEF p.m.) Response During the Last Week on Treatment</title>
          <description>MMRM results. Response was defined as change from baseline at the end of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. Weekly means obtained during the last week of each period of randomised treatment will be compared (measured by patients at home using the AM2+ device).</description>
          <population>FAS reduced to patients with non-missing evening PEF data.</population>
          <units>Litre/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="146"/>
                <count group_id="O4" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.833" spread="4.363"/>
                    <measurement group_id="O2" value="25.084" spread="4.331"/>
                    <measurement group_id="O3" value="18.410" spread="4.331"/>
                    <measurement group_id="O4" value="25.414" spread="4.348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>21.251</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.770</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>13.840</ci_lower_limit>
            <ci_upper_limit>28.662</ci_upper_limit>
            <estimate_desc>Tio R1.25 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>14.577</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.770</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>7.166</ci_lower_limit>
            <ci_upper_limit>21.988</ci_upper_limit>
            <estimate_desc>Tio R2.5 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>21.581</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.773</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>14.166</ci_lower_limit>
            <ci_upper_limit>28.997</ci_upper_limit>
            <estimate_desc>Tio R5 qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PEF Variability Response (Last Week on Treatment)</title>
        <description>MMRM results. Response was defined as change from baseline at the end of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. PEF variability is the absolute difference between morning and evening PEF value divided by the mean of these two values, expressed as a percent . Weekly means obtained during the last week of each period of randomised treatment will be compared.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>FAS reduced to patients with non-missing morning and evening PEF data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo qd in the evening delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25 qd</title>
            <description>Tiotropium 1.25 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5 qd</title>
            <description>Tiotropium 2.5 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
        </group_list>
        <measure>
          <title>PEF Variability Response (Last Week on Treatment)</title>
          <description>MMRM results. Response was defined as change from baseline at the end of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. PEF variability is the absolute difference between morning and evening PEF value divided by the mean of these two values, expressed as a percent . Weekly means obtained during the last week of each period of randomised treatment will be compared.</description>
          <population>FAS reduced to patients with non-missing morning and evening PEF data.</population>
          <units>Percentage of the mean daily PEF</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="146"/>
                <count group_id="O4" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.171" spread="0.615"/>
                    <measurement group_id="O2" value="-0.285" spread="0.609"/>
                    <measurement group_id="O3" value="-0.711" spread="0.609"/>
                    <measurement group_id="O4" value="-0.248" spread="0.612"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8574</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.114</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.635</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.363</ci_lower_limit>
            <ci_upper_limit>1.134</ci_upper_limit>
            <estimate_desc>Tio R1.25 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3954</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.540</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.635</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.789</ci_lower_limit>
            <ci_upper_limit>0.708</ci_upper_limit>
            <estimate_desc>Tio R2.5 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9034</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.077</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.636</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.327</ci_lower_limit>
            <ci_upper_limit>1.173</ci_upper_limit>
            <estimate_desc>Tio R5 qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Puffs of Rescue Medication During the Whole Day (Last Week on Treatment, Response Values)</title>
        <description>MMRM results. Response was defined as change from baseline at the end of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. Weekly means obtained during the last week of each period of randomised treatment will be compared (measured by patients at home using the AM2+ device).</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>FAS reduced to patients with non-missing data for rescue medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo qd in the evening delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25 qd</title>
            <description>Tiotropium 1.25 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5 qd</title>
            <description>Tiotropium 2.5 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Puffs of Rescue Medication During the Whole Day (Last Week on Treatment, Response Values)</title>
          <description>MMRM results. Response was defined as change from baseline at the end of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. Weekly means obtained during the last week of each period of randomised treatment will be compared (measured by patients at home using the AM2+ device).</description>
          <population>FAS reduced to patients with non-missing data for rescue medication.</population>
          <units>Puffs</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="146"/>
                <count group_id="O4" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.569" spread="0.122"/>
                    <measurement group_id="O2" value="-0.802" spread="0.121"/>
                    <measurement group_id="O3" value="-0.783" spread="0.121"/>
                    <measurement group_id="O4" value="-0.769" spread="0.122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0296</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.233</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.107</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.443</ci_lower_limit>
            <ci_upper_limit>-0.023</ci_upper_limit>
            <estimate_desc>Tio R1.25 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0454</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.214</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.107</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.424</ci_lower_limit>
            <ci_upper_limit>-0.004</ci_upper_limit>
            <estimate_desc>Tio R2.5 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0610</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.201</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.107</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.410</ci_lower_limit>
            <ci_upper_limit>0.009</ci_upper_limit>
            <estimate_desc>Tio R5 qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Puffs of Rescue Medication During Daytime (Last Week on Treatment, Response Values)</title>
        <description>MMRM results. Response was defined as change from baseline at the end of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. Weekly means obtained during the last week of each period of randomised treatment will be compared (measured by patients at home using the AM2+ device).</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>FAS reduced to patients with non-missing data for rescue medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo qd in the evening delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25 qd</title>
            <description>Tiotropium 1.25 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5 qd</title>
            <description>Tiotropium 2.5 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Puffs of Rescue Medication During Daytime (Last Week on Treatment, Response Values)</title>
          <description>MMRM results. Response was defined as change from baseline at the end of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. Weekly means obtained during the last week of each period of randomised treatment will be compared (measured by patients at home using the AM2+ device).</description>
          <population>FAS reduced to patients with non-missing data for rescue medication.</population>
          <units>Puffs</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="146"/>
                <count group_id="O4" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.314" spread="0.071"/>
                    <measurement group_id="O2" value="-0.463" spread="0.071"/>
                    <measurement group_id="O3" value="-0.452" spread="0.071"/>
                    <measurement group_id="O4" value="-0.425" spread="0.071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0183</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.149</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.063</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.273</ci_lower_limit>
            <ci_upper_limit>-0.025</ci_upper_limit>
            <estimate_desc>Tio R1.25 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0288</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.138</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.063</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.262</ci_lower_limit>
            <ci_upper_limit>-0.014</ci_upper_limit>
            <estimate_desc>Tio R2.5 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0781</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.111</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.063</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.235</ci_lower_limit>
            <ci_upper_limit>0.013</ci_upper_limit>
            <estimate_desc>Tio R5 qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Puffs of Rescue Medication During Nighttime (Last Week on Treatment, Response Values)</title>
        <description>MMRM results. Response was defined as change from baseline at the end of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. Weekly means obtained during the last week of each period of randomised treatment will be compared (measured by patients at home using the AM2+ device).</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>FAS reduced to patients with non-missing data for rescue medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo qd in the evening delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25 qd</title>
            <description>Tiotropium 1.25 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5 qd</title>
            <description>Tiotropium 2.5 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Puffs of Rescue Medication During Nighttime (Last Week on Treatment, Response Values)</title>
          <description>MMRM results. Response was defined as change from baseline at the end of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. Weekly means obtained during the last week of each period of randomised treatment will be compared (measured by patients at home using the AM2+ device).</description>
          <population>FAS reduced to patients with non-missing data for rescue medication.</population>
          <units>Puffs</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="146"/>
                <count group_id="O4" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.273" spread="0.064"/>
                    <measurement group_id="O2" value="-0.357" spread="0.063"/>
                    <measurement group_id="O3" value="-0.341" spread="0.063"/>
                    <measurement group_id="O4" value="-0.360" spread="0.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1303</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.084</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.055</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.193</ci_lower_limit>
            <ci_upper_limit>0.025</ci_upper_limit>
            <estimate_desc>Tio R1.25 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2191</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.068</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.055</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.177</ci_lower_limit>
            <ci_upper_limit>0.041</ci_upper_limit>
            <estimate_desc>Tio R2.5 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1163</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.087</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.056</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.196</ci_lower_limit>
            <ci_upper_limit>0.022</ci_upper_limit>
            <estimate_desc>Tio R5 qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Night Awakenings During the Last Week on Treatment (Score, Response Values)</title>
        <description>MMRM results. Response was defined as change from baseline at the end of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. Weekly means obtained during the last week of each period of randomised treatment will be compared (measured by patients at home using the AM2+ device).</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>FAS reduced to patients with non-missing data for nighttime awakenings</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo qd in the evening delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25 qd</title>
            <description>Tiotropium 1.25 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5 qd</title>
            <description>Tiotropium 2.5 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Night Awakenings During the Last Week on Treatment (Score, Response Values)</title>
          <description>MMRM results. Response was defined as change from baseline at the end of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. Weekly means obtained during the last week of each period of randomised treatment will be compared (measured by patients at home using the AM2+ device).</description>
          <population>FAS reduced to patients with non-missing data for nighttime awakenings</population>
          <units>Night awakenings</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="146"/>
                <count group_id="O4" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.156" spread="0.034"/>
                    <measurement group_id="O2" value="-0.166" spread="0.034"/>
                    <measurement group_id="O3" value="-0.162" spread="0.034"/>
                    <measurement group_id="O4" value="-0.187" spread="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7501</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.010</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.032</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.073</ci_lower_limit>
            <ci_upper_limit>0.052</ci_upper_limit>
            <estimate_desc>Tio R1.25 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8401</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.006</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.032</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.069</ci_lower_limit>
            <ci_upper_limit>0.056</ci_upper_limit>
            <estimate_desc>Tio R2.5 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3237</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.031</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.032</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.094</ci_lower_limit>
            <ci_upper_limit>0.031</ci_upper_limit>
            <estimate_desc>Tio R5 qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 Area Under the Curve Within 24 Hours (h) Response (FEV1 AUC0-12h, FEV1 AUC12-24h, FEV1 AUC0-24h)</title>
        <description>MMRM results. Response was defined as change from baseline at the end of of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. FEV1 AUC0-12, FEV1 AUC12-24 and FEV1 AUC0-24 were calculated using the trapezoidal rule divided by the observation time (12h resp. 24h) to report in litres.</description>
        <time_frame>10 minutes (min) before drug administration and 30 min, 1h, 2h, 3h, 4h, 11h 50min, 12h 30min, 13h, 14h, 15h, 16h, 18h, 20h, 22h, 23h, 23h 50min after drug administration</time_frame>
        <population>FAS24 was defined as all patients in the FAS who gave informed consent for the 24-h PFT and who participated in this optional PFT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo qd in the evening delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25 qd</title>
            <description>Tiotropium 1.25 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5 qd</title>
            <description>Tiotropium 2.5 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Area Under the Curve Within 24 Hours (h) Response (FEV1 AUC0-12h, FEV1 AUC12-24h, FEV1 AUC0-24h)</title>
          <description>MMRM results. Response was defined as change from baseline at the end of of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. FEV1 AUC0-12, FEV1 AUC12-24 and FEV1 AUC0-24 were calculated using the trapezoidal rule divided by the observation time (12h resp. 24h) to report in litres.</description>
          <population>FAS24 was defined as all patients in the FAS who gave informed consent for the 24-h PFT and who participated in this optional PFT.</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FEV1 AUC0-12h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.013" spread="0.058"/>
                    <measurement group_id="O2" value="0.105" spread="0.055"/>
                    <measurement group_id="O3" value="0.134" spread="0.054"/>
                    <measurement group_id="O4" value="0.128" spread="0.054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1 AUC12-24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.012" spread="0.061"/>
                    <measurement group_id="O2" value="0.093" spread="0.058"/>
                    <measurement group_id="O3" value="0.148" spread="0.058"/>
                    <measurement group_id="O4" value="0.208" spread="0.057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1 AUC0-24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.001" spread="0.057"/>
                    <measurement group_id="O2" value="0.099" spread="0.054"/>
                    <measurement group_id="O3" value="0.141" spread="0.054"/>
                    <measurement group_id="O4" value="0.168" spread="0.053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison vs. Placebo for AUC0-12h</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1402</p_value>
            <p_value_desc>MMRM, adjusted for treatment, period, patient and study baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.118</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.079</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.040</ci_lower_limit>
            <ci_upper_limit>0.276</ci_upper_limit>
            <estimate_desc>Tio R1.25 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison vs. Placebo for AUC0-12h</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0656</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.148</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.079</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.010</ci_lower_limit>
            <ci_upper_limit>0.305</ci_upper_limit>
            <estimate_desc>Tio R2.5 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison vs. Placebo for AUC0-12h</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0766</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.142</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.079</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.015</ci_lower_limit>
            <ci_upper_limit>0.299</ci_upper_limit>
            <estimate_desc>Tio R5 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison vs. Placebo for AUC12-24h</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3371</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.081</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.084</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.086</ci_lower_limit>
            <ci_upper_limit>0.249</ci_upper_limit>
            <estimate_desc>Tio R1.25 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison vs. Placebo for AUC12-24h</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1097</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.136</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.084</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.031</ci_lower_limit>
            <ci_upper_limit>0.303</ci_upper_limit>
            <estimate_desc>Tio R2.5 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison vs. Placebo for AUC12-24h</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0220</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.196</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.084</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.029</ci_lower_limit>
            <ci_upper_limit>0.363</ci_upper_limit>
            <estimate_desc>Tio R5 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison vs. Placebo for AUC0-24h</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2062</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.100</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.078</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.056</ci_lower_limit>
            <ci_upper_limit>0.256</ci_upper_limit>
            <estimate_desc>Tio R1.25 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison vs. Placebo for AUC0-24h</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0731</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.142</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.078</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.014</ci_lower_limit>
            <ci_upper_limit>0.297</ci_upper_limit>
            <estimate_desc>Tio R2.5 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison vs. Placebo for AUC0-24h</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0333</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.169</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.078</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.014</ci_lower_limit>
            <ci_upper_limit>0.324</ci_upper_limit>
            <estimate_desc>Tio R5 qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC Area Under the Curve Within 24 Hours (h) Response (FVC AUC0-12h, FVC AUC12-24h, FVC AUC0-24h)</title>
        <description>MMRM results. Response was defined as change from baseline at the end of of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. FVC AUC0-12, FVC AUC12-24 and FVC AUC0-24 were calculated using the trapezoidal rule divided by the observation time (12h resp. 24h) to report in litres.</description>
        <time_frame>10 minutes (min) before drug administration and 30 min, 1h, 2h, 3h, 4h, 11h 50min, 12h 30min, 13h, 14h, 15h, 16h, 18h, 20h, 22h, 23h, 23h 50min after drug administration</time_frame>
        <population>FAS24 was defined as all patients in the FAS who gave informed consent for the 24-h PFT and who participated in this optional PFT.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo qd in the evening delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Tio R1.25 qd</title>
            <description>Tiotropium 1.25 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R2.5 qd</title>
            <description>Tiotropium 2.5 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
          <group group_id="O4">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC Area Under the Curve Within 24 Hours (h) Response (FVC AUC0-12h, FVC AUC12-24h, FVC AUC0-24h)</title>
          <description>MMRM results. Response was defined as change from baseline at the end of of each 4-week treatment period. Means are adjusted for treatment, period, patient and study baseline. FVC AUC0-12, FVC AUC12-24 and FVC AUC0-24 were calculated using the trapezoidal rule divided by the observation time (12h resp. 24h) to report in litres.</description>
          <population>FAS24 was defined as all patients in the FAS who gave informed consent for the 24-h PFT and who participated in this optional PFT.</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FVC AUC0-12h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.052" spread="0.072"/>
                    <measurement group_id="O2" value="0.064" spread="0.068"/>
                    <measurement group_id="O3" value="0.157" spread="0.068"/>
                    <measurement group_id="O4" value="0.115" spread="0.068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC AUC12-24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.021" spread="0.076"/>
                    <measurement group_id="O2" value="0.046" spread="0.071"/>
                    <measurement group_id="O3" value="0.177" spread="0.071"/>
                    <measurement group_id="O4" value="0.160" spread="0.071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC AUC0-24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.036" spread="0.072"/>
                    <measurement group_id="O2" value="0.055" spread="0.067"/>
                    <measurement group_id="O3" value="0.167" spread="0.067"/>
                    <measurement group_id="O4" value="0.137" spread="0.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison vs. Placebo for AUC0-12h</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2451</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.116</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.099</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.081</ci_lower_limit>
            <ci_upper_limit>0.312</ci_upper_limit>
            <estimate_desc>Tio R1.25 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison vs. Placebo for AUC0-12h</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0379</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.209</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.099</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.012</ci_lower_limit>
            <ci_upper_limit>0.405</ci_upper_limit>
            <estimate_desc>Tio R2.5 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison vs. Placebo for AUC0-12h</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0957</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.167</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.099</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.030</ci_lower_limit>
            <ci_upper_limit>0.363</ci_upper_limit>
            <estimate_desc>Tio R5 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison vs. Placebo for AUC12-24h</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5207</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.067</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.104</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.139</ci_lower_limit>
            <ci_upper_limit>0.273</ci_upper_limit>
            <estimate_desc>Tio R1.25 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison vs. Placebo for AUC12-24h</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0606</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.198</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.104</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.009</ci_lower_limit>
            <ci_upper_limit>0.404</ci_upper_limit>
            <estimate_desc>Tio R2.5 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison vs. Placebo for AUC12-24h</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0855</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.181</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.104</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.026</ci_lower_limit>
            <ci_upper_limit>0.387</ci_upper_limit>
            <estimate_desc>Tio R5 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison vs. Placebo for AUC0-24h</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3564</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.091</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.099</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.104</ci_lower_limit>
            <ci_upper_limit>0.287</ci_upper_limit>
            <estimate_desc>Tio R1.25 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison vs. Placebo for AUC0-24h</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0424</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.203</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.099</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.007</ci_lower_limit>
            <ci_upper_limit>0.399</ci_upper_limit>
            <estimate_desc>Tio R2.5 qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison vs. Placebo for AUC0-24h</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0815</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.174</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.099</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.022</ci_lower_limit>
            <ci_upper_limit>0.370</ci_upper_limit>
            <estimate_desc>Tio R5 qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks + 30 days if in last period</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Matching Placebo qd in the evening delivered by the Respimat inhaler.</description>
        </group>
        <group group_id="E2">
          <title>Tio R1.25 qd</title>
          <description>Tiotropium 1.25 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
        </group>
        <group group_id="E3">
          <title>Tio R2.5 qd</title>
          <description>Tiotropium 2.5 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
        </group>
        <group group_id="E4">
          <title>Tio R5 qd</title>
          <description>Tiotropium 5 mcg qd in the evening delivered by the Respimat inhaler as add-on therapy to ICS.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

